CommercialDocumentationMedium impact
08.01.66e, Cemiplimab-rwlc (Libtayo®)
Independence Blue Cross·Oncology, Dermatology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.66e for Cemiplimab-rwlc (Libtayo®) has been updated effective 12/29/2025 with changes to medical necessity criteria, medical coding, and general policy guidelines. The billing team must review updated coverage requirements and coding instructions for this PD-L1 inhibitor immunotherapy to ensure accurate claim submission and avoid denials.
Action Required
By 12/29/2025: Billing team must access the full policy text at the provided URL and review all updates to medical necessity criteria, coding requirements, and coverage guidelines for Cemiplimab-rwlc (Libtayo®). Update billing system edits and prior authorization templates to reflect new requirements. Notify providers of any documentation changes needed for claim submission. Review any affected HCPCS or CPT codes associated with this drug administration and update encounter forms accordingly. Failure to implement changes may result in claim denials or delayed payments.